Andersen Global Expands African Presence with Addition of Bravura

 (BUSINESS WIRE)--Andersen Global strengthens its presence in Africa through a Collaboration Agreement with Bravura, a leading independent tax and financial advisory firm based in South Africa and Namibia.

Founded in 1999, Bravura provides tax and financial advisory solutions to listed and private companies, entrepreneurs, and high-net-worth families across the region. Bravura combines deep financial expertise with an entrepreneurial mindset to deliver tailored strategies that drive value. The firm’s multidisciplinary team provides advisory services in mergers and acquisitions, capital raising, corporate restructuring, and succession planning. Additionally, the firm offers tax and accounting strategy, international tax structuring, global mobility, and exchange control compliance solutions.

“At Bravura, we’re driven to redefine standards and deliver bespoke, results-driven solutions that create lasting value for our clients,” said Ian Matthews, head of business development at Bravura. “Our collaboration with Andersen Global enables us to leverage its expansive platform and build working relationships with professionals globally, who share our unwavering commitment to excellence, integrity, and performance.”

Global Chairman and CEO of Andersen, Mark L. Vorsatz added, “Bravura’s proven track record and forward-thinking approach position them as a valuable addition to our platform. The firm’s deep expertise and knowledge of the local market complement our capabilities in Africa and enhance our ability to deliver seamless, multidisciplinary solutions to clients in the region and globally.”

Andersen Global is an international association of legally separate, independent member firms comprised of tax, legal, and valuation professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310549728/en/

Permalink

https://www.aetoswire.com/en/news/1003202653747

Contacts

Megan Tsuei

Andersen Global

415-764-2700

Kinaxis Goes All-In on Innovation at Upcoming Kinexions in Las Vegas

  Annual customer conference will bring together global supply chain leaders to explore the latest trends, best practices and technologies in AI-powered planning, decision-making and agentic innovation

(BUSINESS WIRE)--Registration is officially open for Kinexions North America, the premier global supply chain orchestration conference hosted by Kinaxis® Inc. (TSX: KXS). Taking place June 1–3 in Las Vegas, Nevada, the event brings together supply chain leaders, innovators and practitioners from around the world to explore how organizations can leverage AI-driven strategies and technologies to connect data, people and decisions.

After a year defined by market volatility, geopolitical risk and disruption, this year’s conference will focus on how intelligent supply chain orchestration enables organizations to move beyond reactive planning to building true enterprise adaptability. The program promises to be the most immersive and future-forward Kinexions yet, with renowned author, entrepreneur and innovation expert, Peter Hinssen confirmed as a featured keynote address.

“Kinexions has always been the place where the best in supply chain come together to calibrate and share ideas, rethink what’s possible and accelerate real innovation — and 2026 is going to set a new bar,” said Kinaxis Chief Executive Officer, Razat Gaurav. “What I’m hearing consistently from our customers is the challenge of making smart supply chain decisions with unprecedented levels of change and uncertainty. The leaders pulling ahead are the ones embracing outcomes‑driven thinking and leveraging AI‑powered agentic orchestration. We’re excited to welcome our community of customers and partners as they come together for three days of impactful networking, learning, and shaping what’s next.”

Throughout the conference, attendees will hear directly from numerous Kinaxis customers, many of which are operating some of the world’s most complex supply chains, and will have the opportunity to see firsthand how the Kinaxis Maestro™ platform and Maestro Agents are helping to transform today’s supply chain environments and dive further into how AI is reshaping decision making.

Key highlights for the 2026 conference include:

• Mainstage keynote from Peter Hinssen, who will share an exclusive perspective on how leaders can turn uncertainty into opportunity and build bold, future‑ready organizations in a “Never Normal” world, following the release of his latest book ‘The Uncertainty Principle’.
• A robust lineup of customer speakers from some of the world’s most complex and extensive supply chains.
• Dozens of sessions, hands‑on training, deep‑dive technical workshops, and product innovation showcases designed to help organizations accelerate value adoption.
• The annual Kinaxis Customer Awards, recognizing individuals and organizations leading the way in innovation, transformation, and supply chain excellence.
• Access to exclusive product announcements, networking receptions, and the full Kinaxis community experience.

Hosted at The Cosmopolitan of Las Vegas, Kinexions will offer a vibrant and immersive backdrop for learning and connection, blending modern luxury with the energy of one of the world’s most iconic destinations. Attendees will gain early visibility into new platform innovations and expanded capabilities within Maestro, reinforcing the Kinaxis commitment to advance supply chain orchestration beyond traditional planning processes.

Registration for Kinexions North America is open now at www.kinexions.com.

To learn more about Kinaxis and its industry‑leading supply chain orchestration platform visit www.kinaxis.com.

About Kinaxis

Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Source: Kinaxis Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309118533/en/

Permalink

https://www.aetoswire.com/en/news/54442264

Contacts

Media Relations

Erin Boyle | Kinaxis

eboyle@kinaxis.com

+1 519-574-4065

Investor Relations

Rick Wadsworth | Kinaxis

rwadsworth@kinaxis.com

613-907-7613

Estithmar Holding Net Profit Surges 122% to QAR 938 Million; Revenue Rises 54% to QAR 6.4 Billion for the Year Ended 31 December 2025

Doha, Qatar - Tuesday, 10. March 2026

- Sustainable Growth Driven by International Expansion

- Significant Increase Across Key Metrics

 

Estithmar Holding Q.P.S.C. has announced its financial results for the year ended 31 December 2025. The group reported a 54% increase in revenue to QAR 6.4 billion, compared with QAR 4.2 billion in 2024. Gross profit rose to QAR 2.1 billion, up from QAR 1 billion in 2024, representing growth of 111%. EBITDA reached QAR 1.5 billion, an increase of 102% year-on-year.

Net profit climbed 122% compared with 2024, reaching QAR 938 million. Earnings per share increased by 145% to QAR 0.264.

The growth in net profit was primarily driven by higher revenues, particularly from the specialized contracting and healthcare sectors. The results reflect the group’s ability to convert operational growth into sustainable profitability while maintaining financial discipline.

Total assets increased by 23% in 2025 compared with the previous year, largely due to new projects added to Estithmar Holding’s portfolio, including Baghdad International Hospital in Iraq.

The Board of Directors has recommended the distribution of dividends equivalent to 20% of the company’s share capital, in the form of 2 bonus shares for every 10 shares held.

The 2025 results show a marked improvement across key financial indicators, supported by expansion in the group’s core sectors, improved project execution, and enhanced operational efficiency across its businesses. These results demonstrate Estithmar Holding’s ability to scale its operations while maintaining financial discipline and strengthening profitability.

Commenting on the results, Juan Leon, Holding Chief Executive Officer of Estithmar Holding, said: “2025 represents an important milestone in Estithmar Holding’s journey. Our strong financial performance reflects the successful execution of our growth and expansion strategy across the group’s sectors, as well as the considerable efforts of our teams across multiple markets.

“Achieving strong growth across all key financial indicators highlights the resilience of our diversified business model and our continued focus on operational excellence, maintaining financial discipline and governance. As we expand our footprint and strengthen our presence in regional markets, we remain committed to delivering sustainable value to shareholders while exploring new growth opportunities.”

“The group’s strong financial position allows us to move forward with upcoming strategic initiatives, while also evaluating potential opportunities in capital markets to support the next phase of the group’s expansion”, Leon added.

The specialized contracting group accounted for the largest share of revenue contribution in 2025. The sector delivered strong activity both locally and regionally, particularly in Saudi Arabia, Syria, Algeria and Iraq. During the year, the industrial and specialized contracting businesses continued to expand, executing major projects across 12 countries. These include large-scale developments such as the Red Sea projects in Saudi Arabia, infrastructure projects in Syria, and several major developments in Qatar, including educational facilities.

During the year, the group secured 262 new contracts, reflecting growing confidence in its companies as partners for the delivery of major projects.

Estithmar Holding’s healthcare group, through its subsidiary Apex Health, also continued to deliver sustainable growth, driven by the implementation of its regional hospital management and operations model, including in Iraq and Libya.

Within Qatar, the group’s hospitals; The View Hospital and the Korean Medical Center continued to build patient trust through adherence to the highest international quality standards and by hosting leading global medical professionals. In 2025, The View Hospital performed more than 100 robotic surgeries.

Read more  

Permalink

https://www.aetoswire.com/en/news/1003202653750

Contacts

Nesrine Nacef

Corporate Communications Manager

0097466157504

TTNE Announces the World Sauna Award “SAUNA37 2026”

 TOKYO - Tuesday, 10. March 2026 AETOSWire 

(BUSINESS WIRE)--TTNE Inc. today announced “SAUNA37 2026”, the world sauna award recognizing 37 sauna destinations worldwide

Through this initiative, we aim to contribute to the global growth of sauna culture and create a future where people around the world can lead happier and healthier lives through saunas.

TTNE was founded by Totonoe Oyakata (Dai Matsuo) and Sauna Master (Daisuke Akiyama), who have personally experienced some of the world's finest saunas. Their desire to establish a similar deep-rooted sauna culture in Japan led to the creation of TTNE.

As people once again have the opportunity to explore sauna experiences around the world, SAUNA37 aims to introduce the diverse and unique sauna facilities and cultures across the globe. Through this initiative, we seek to further evolve Japan’s sauna culture while also sharing it with the world.

TTNE remains committed to the global evolution of sauna culture, continuously working to inspire and promote its growth worldwide.

SAUNA37

https://www.sauna37.com/

- Nominated 37 sauna facilities -

38° THE BATHHOUSE (Australia)

Adventuremine (Sweden)

Allas Pool (Finland)

Aquardens Verona Spa (Italy)

ARC (UK)

Arctic Bath (Sweden)

Biome by Corinthia London (UK)

Blue Lagoon Iceland (Iceland)

Capybara Bathing (Australia)

Chochołowskie Termy (Poland)

Great Jones Spa (USA)

Hotel Jungbrunn (Austria)

Hotel Krallerhof (Austria)

Hotel Tjampuhan and Spa (Indonesia)

KAN NO JIGOKU RYOKAN (Japan)

KEDR Spa & Sauna (Thailand)

Kokyu no Ma, Shiriuchi Onsen (Japan)

Les Bains de Lavey (Switzerland)

Lonna Sauna (Finland)

Nowhere Baths (Singapore)

OCHIAIRO (Japan)

Rudas Thermal Bath (Hungary)

SATAMA Sauna Resort & Spa (Germany)

Scandinave Spa Whistler (Canada)

Sense Of Self (Australia)

Serlachius Art Sauna (Finland)

Soak Bathhouse - South Yarra (Australia)

Soria Moria Sauna (Norway)

SPA ONE (Netherlands)

Strøm Nordic Spa (Canada)

Széchenyi Thermal Bath and Swimming Pool (Hungary)

Tamina Therme (Switzerland)

Terme Olimia (Slovenia)

Thermen Maarssen (Netherlands)

Tupaswilla (Finland)

V Spa Hotel and Conference Centre (Estonia)

Vabali Spa Hamburg (Germany)

TTNE

Official site & Instagram

TTNE: https://ttne.jp @ttne_official

SHOP TTNE: https://www.ttne.shop

SAUNA SELECT: https://sauna-select.com

SAUNACHELIN: https://www.saunachelin.com @saunachelin_official

SAUNA37: http://sauna37.com @sauna37_official

HARVIA: https://www.harvia.com, https://harvia.jp, @harviaglobal, @harvia.jp

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260308149186/en/

Permalink

https://www.aetoswire.com/en/news/54441789

Contacts

 

TTNE Inc.

contact@ttne.jp

WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel

 BOSTON - 

WHOOP deepens investment in women’s physiology with clinically meaningful lab testing, predictive symptom modeling, and new Menstrual Cycle White Paper

 

(BUSINESS WIRE)--WHOOP, the human performance company, today unveiled multiple initiatives and new clinically-backed features, including the coming launch of the company’s Women's Health Specialized Blood Biomarker Panel. Building on the WHOOP Advanced Labs Baseline Panel launched last year, the Women’s Health Specialized Blood Biomarker Panel adds 11 clinically backed, female-specific blood biomarkers that expand insight into areas that are frequently under-measured or misinterpreted in traditional women’s health testing. WHOOP has also announced a new Hormonal Symptom Insights and Predictions update, along with a comprehensive Menstrual Cycle White Paper detailing the science behind its cycle modeling.

These initiatives reflect the company’s commitment to advancing women’s health in an area that has historically been under-researched and underrepresented in data, clinical standards, and performance science. Women represent a growing share of new WHOOP members, with 150% year-over-year growth, signaling increasing demand for health insights that account for hormonal dynamics, training response, and long-term health outcomes. Women also engage with WHOOP AI approximately 30% more than male members, reflecting strong demand for intelligent, personalized women’s health support.

“Unlike solutions that focus on isolated conditions or single life stages, WHOOP delivers a connected health experience informed by one of the world’s largest datasets on women’s physiology,” said Alex Vannoni, Head of Healthcare Product at WHOOP. “We’re not just helping women track their cycles. We’re helping them understand how their physiology evolves over time - and giving them tools to act on it.”

WHOOP Advanced Labs: Women’s Health Specialized Panel

The Advanced Labs baseline and new Women’s Health Specialized Panel create a progressive, female-first testing pathway that supports women across all life stages.

The new panel, launching next month, includes critical biomarkers that dive deeper into cycle regulation and hormonal transitions, including perimenopause, thyroid function, nutrient sufficiency, and bone–metabolic resilience. The biomarkers tested are: Anti-Müllerian Hormone (AMH), Progesterone, Prolactin and Thyroid Peroxidase Antibodies (TPOAb), Free T4, Free T3, Leptin, Vitamin B12 (Cobalamin), Folate, Magnesium and Phosphate (as Phosphorus).

By layering lab data on top of continuous wearable metrics and AI-modelling, WHOOP enables members to see how biomarkers correlate with recovery trends, strain tolerance, sleep efficiency, and stress patterns over time - turning static lab results into dynamic insight.

Members will be able to purchase the Women’s Health Specialized Panel via the WHOOP app.

Hormonal Symptom Insights and Predictions

WHOOP is also expanding its Menstrual Cycle Insights and Pregnancy Insights offering, with a new update - Hormonal Symptom Insights and Predictions. Within the WHOOP app, menstruating members will now receive a personalized model of their cycle that adapts over time, based on their unique physiological data and historical patterns.

Within the WHOOP app, members will now have access to key data about their cycle that allows them to accurately adjust their daily routines, fitness regimes, and recovery practices and anticipate potential symptoms rather than simply recording them. This includes access to:

A dynamic date window for the next period, allowing for more anticipation around the menstrual cycle

Tracked trends in cycle length, period length, and variability, flagging irregular patterns before larger issues persist

Analyzed individual symptom patterns to anticipate when symptoms are most likely to occur

As part of the latest Cycle Insights updates, the feature now integrates with WHOOP Advanced Labs. This integration enables WHOOP to deliver personalized biomarker ranges - categorized as ‘optimal,’ ‘sufficient,’ or ‘out of range’ - based on where a member is in their cycle. When a member completes a blood draw, WHOOP automatically applies the appropriate reference range aligned to their recorded cycle phase, ensuring results are interpreted through the lens of their physiology. It’s another example of how women’s unique biology is embedded into every WHOOP product and feature.

Menstrual Cycle White Paper

WHOOP has also published a comprehensive Menstrual Cycle White Paper outlining the research, methodology, and validation behind its modeling approach. The white paper proves how continuous physiological monitoring improves prediction accuracy over time, how the system accounts for variable cycles, perimenopause, and hormonal birth control, and how prediction windows dynamically widen or narrow based on variability.

By bringing continuous, longitudinal visibility to cycle patterns, WHOOP aims to increase health literacy and close a long-standing data gap in women’s health.

“What makes this powerful isn’t any single data point - it’s how the system comes together," said Emily Capodillupo, Senior Vice President of Research, Algorithms, and Data at WHOOP. “Women don’t experience their physiology in silos. Hormones influence sleep, sleep affects recovery, and recovery shapes training response. By modeling these interactions over time - across continuous biometrics, lab data, and behavior - we can deliver guidance that reflects the full system, not just a snapshot.”

With the support of the WHOOP Medical Advisory Board, including Dr. Robin Berzin and Dr. Hazel Wallace, and in tandem with their recent collaboration with Clue, a leader in menstrual and reproductive health, WHOOP will continue to drive innovation in women’s health and deliver on the company’s goal of adding one billion healthy years to the planet.

The Women’s Health Specialized Panel, along with additional blood panels, will be available via WHOOP in April. You can find links to imagery in our Digital Press Kit.

*The Women’s Health Specialized Panel will be available exclusively in the US at launch.

About WHOOP:

WHOOP delivers a wearable membership to help people live healthier, longer lives and unlock extraordinary potential. Through a powerful 24/7 wearable with a 14-day battery life, WHOOP provides intelligent health guidance across sleep, recovery, strain, fitness, and long-term wellbeing. The health platform includes an FDA-cleared ECG, a Healthspan longevity feature, Blood Pressure Insights, and Advanced Labs blood biomarker analysis. Peer-reviewed research shows: that members who wear WHOOP daily increase their weekly exercise by more than 90 minutes, gain over two hours of additional sleep per week, and improve heart rate variability by 10%.

Trusted by millions of members worldwide including athletes, global leaders, military operators, executives, and artists, WHOOP has become a modern symbol of disciplined, intentional living. WHOOP was founded in 2012 and is headquartered in Boston. The company has raised more than $400 million in venture capital, ships to 56 countries, and operates in six languages. Learn more at whoop.com and connect with WHOOP on Instagram, LinkedIn, X, Facebook, and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310966566/en/

Permalink

https://aetoswire.com/en/news/54439889

Contacts

 

Taylor (Georgeson) Bonner

whoop@jacktaylorpr.com

Jack Taylor Worldwide

Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin

 ZUG, Switzerland -

Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power™ Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience

Delivers advanced antioxidant protection by day1 and accelerated repair by night, with visible results in as little as 7 days2

In global testing, Gallic Acid demonstrated 2x greater antioxidant efficacy than Vitamin C3

Co-developed with dermatologists and rigorously tested for sensitive skin to deliver high performance without compromising tolerance

 

(BUSINESS WIRE)--Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin.

While antioxidant serums are a cornerstone of modern skincare, the category has largely been developed without sensitive skin in mind. Despite rapid growth, many formulations prioritize potency over skin compatibility, narrowing options for those who require both efficacy and tolerance. This gap is especially significant given that, globally, an estimated 78% of people report experiencing skin sensitivity4, according to research from Galderma’s Global Sensitive Skincare Faculty (GSSF). Further Galderma research demonstrates that sensitive skin exhibits 16% higher oxidative stress compared to non-sensitive skin under modern environmental conditions5. Together, these findings underscore the need for solutions designed to meet the needs of sensitive skin across ages, environments, and lifestyles.

Cetaphil’s AM/PM Antioxidant Serums were developed to address this unmet need, introducing a new approach that pairs advanced antioxidant science with formulations specifically engineered for sensitive skin, delivering performance without compromising barrier health.

Breakthrough antioxidant technology designed for sensitive skin

At the core of Cetaphil’s AM/PM Antioxidant Serums is a unique Gallic-AOX Power™ Technology, a proprietary antioxidant complex that redefines what antioxidant care can look like for sensitive skin. Combining Gallic Acid and Vitamin E, this advanced technology neutralizes free radicals more efficiently than traditional antioxidants like vitamin C, helping sensitive skin defend itself against oxidative stress without triggering irritation.

In global laboratory testing, Gallic Acid demonstrated more than twice the antioxidant efficacy of Vitamin C3, establishing a new benchmark in antioxidant performance. In global clinical evaluations, consistent use of the AM/PM system resulted in skin that is up to 7x stronger against daily stressors6, reinforcing the role of targeted antioxidant care in supporting barrier health for sensitive skin.

The technology builds on emerging research linking oxidative stress, lifestyle factors, and barrier disruption to periods of heightened skin sensitivity, and is further supported by new research published in collaboration with Galderma’s Global Sensitive Skincare Faculty (GSSF), reinforcing the connection between oxidative stress and sensitive skin.

Each formula was co-developed with dermatologists and clinically tested on sensitive skin to ensure both efficacy and long-term tolerability. This science-led approach reflects Cetaphil’s continued focus on aligning advanced efficacy with the unique needs of sensitive skin.

 

“Sensitive skin experiences oxidative stress just like all skin types; the difference is how it responds. With the Cetaphil AM/PM Antioxidant Serums, we focused on developing an antioxidant system that supports sensitive skin, aligning protection and repair with the skin’s natural daily rhythm. This launch reflects our continued commitment to advancing sensitive skin science through clinically driven innovation”

 

BILL ANDRIOPOULOUS

HEAD OF GLOBAL MEDICAL AFFAIRS GALDERMA

 

Dermatologists increasingly recognize oxidative stress as a key contributor to skin sensitivity and barrier disruption.

 

"In clinical practice, sensitive skin patients are often told to avoid antioxidant products altogether because many formulas can be difficult to tolerate. What makes this formula so impressive is its breakthrough antioxidant technology: Gallic-AOX Power™, a unique combination of gallic acid and vitamin E that helps counteract oxidative stress. With consistent use, the skin can become visibly stronger and more resilient to daily aggressors to improve overall skin quality”

 

DR. AARON FARBERG

DERMATOLOGIST AND MOHS SURGEON, BAYLOR SCOTT & WHITE HEALTH (U.S.)

 

A new approach to antioxidant care for sensitive skin

Environmental aggressors, lifestyle stress, and overuse of active ingredients can contribute to oxidative stress, weakening the skin barrier and intensifying sensitivity. While oxidative stress affects all skin types, sensitive skin often responds with heightened inflammation, making daily antioxidant care both essential and difficult to tolerate.

Cetaphil’s AM/PM Antioxidant Serums were developed as a complementary day-and-night system, formulated to work in sync with the skin’s natural daily rhythm:

AM Advanced Defense Serum helps defend against daily environmental stressors, including pollution, stress and blue light, while strengthening the skin barrier to leave skin visibly more resilient – powered by niacinamide and triple hyaluronic acid to help hydrate, soothe, and support skin barrier health.

PM Repair & Renew Serum supports overnight recovery, helping to repair the skin barrier and address accumulated damage to restore the appearance of stressed, sensitive skin, delivering 2x faster skin barrier repair overnight7 and visibly plumper, more even-looking skin in as little as seven days8 – with hyaluronic acid, pro-vitamin B5, cica, and bifida ferment to help hydrate, soothe, and support skin recovery.

About Cetaphil®

Over seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula that would clean without stripping and moisturize without clogging. Today, Cetaphil is a dermatologist recommended sensitive skincare brand and is recognized around the world. With the help of leading global skincare experts, they continue to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin's health every day. For more information, visit www.cetaphil.com.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermato-logical Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

Galderma. Data on file. SPR.3438.207553

Galderma. Data on file. SPR.3438.207551.

Galderma Data on files – Gematria reports GD-AP-01a-2023, GD-AP-03-2023 and GD-AP-04-2023​

Vidal SI, et al., Defining the Prevalence, Clinical Characteristics, and Demographic Influences on Patients with Sensitive Skin Syndrome: Insights from the Largest Global Survey of Sensitive Skin EADV Congress; 2025; Paris. Poster.

Galderma data on file, RD.SPR.3438.2017106

Galderma. Data on file. SPR.3438.207557

Galderma. Data on file. SPR.3438.207551

Galderma data on file SPR.3438.207557 2, SPR.3438.207558

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260308270674/en/

Permalink

https://www.aetoswire.com/en/news/54441857

Contacts

 

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Viviana Wiewall

Head of U.S. Communications

viviana.wiewall@galderma.com

+1 (786) 451 77 40

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

 

Kinaxis Announces Amendment to Maximize Size of Normal Course Issuer Bid

 (BUSINESS WIRE)--Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that, further to its previously announced intention to maximize the size of its normal course issuer bid (the “NCIB”), it has received approval from the Toronto Stock Exchange (the “TSX”) to amend (the “Amendment”) the NCIB, effective on March 11, 2026 (the “Effective Date”), to increase the maximum number of common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, the maximum amount allowable under the rules of the TSX. No other terms of the NCIB have been amended. The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million.

In its February 4, 2026 news release, Kinaxis highlighted the rationale for maximizing the NCIB, with Razat Gaurav, chief executive officer, stating, “There is a fundamental misunderstanding of the opportunities and threats from generative and agentic AI to mission-critical enterprise software, like ours, that solves deeply complex problems and enables highly consequential decisions. As a result, the public markets may not be fully reflecting the underlying value of Kinaxis from time to time. We see value to shareholders in maximizing our ability to buy back Shares under the NCIB structure or other structures that may also be available to Kinaxis. Our substantial moat in industry is built on decades of deep domain knowledge, and our Maestro platform represents the most granular and holistic representation of how underlying supply chains operate. Maestro’s predictions, intelligence and prescriptive decisions are made possible by leveraging a fusion of advanced machine learning, optimization and heuristics. These capabilities are fundamental to supply chain planning and decision making and are enhanced, not replaced, by GenAI, composable agentic AI, and the latest semantic and data architectures to achieve the next generation of supply chain orchestration. We are excited about the possibilities.”

The NCIB, which began on November 12, 2025, and will end no later than November 11, 2026, is being conducted on the open market through the facilities of the TSX and/or alternative Canadian trading systems or by such other means as may be permitted by the applicable securities regulators. Except for block purchases permitted under the rules of the TSX, the number of Shares to be purchased per day under the NCIB will not exceed 14,137, which represents 25% of the average daily trading volume of the Shares on the TSX for the six calendar months ended October 31, 2025 (being 56,549 Shares). Kinaxis previously entered into an automatic share repurchase plan under which its designated broker will repurchase Shares pursuant to the NCIB, and the automatic plan, which will be amended as of the Effective Date to account for the Amendment, will continue to apply to the amended NCIB. The actual number of Shares purchased under the NCIB, including under the automatic plan, the timing of such purchases and the price at which Shares are purchased will depend upon future market conditions and will be determined by management of the Company, subject to applicable law and the rules of the TSX. The automatic plan, which was pre-cleared by the TSX, provides for the potential repurchase of Shares at any time, including when Kinaxis ordinarily would not be active in the market due to it being in a blackout period.

Under the NCIB, to date, Kinaxis has repurchased for cancellation an aggregate of 447,738 Shares (at an average price of C$167.50 per Share).

About Kinaxis

Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro™, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain – from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.

Cautionary Note and Forward-Looking Information

This press release contains forward-looking information within the meaning of Canadian securities legislation. Forward-looking information relates to future events or the anticipated performance of Kinaxis and reflects management’s expectations or beliefs regarding such future events. In certain cases, statements that contain forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, or “will be taken”, “occur” or “be achieved” or the negative of these words or comparable terminology. Forward-looking information in this press release includes statements with respect to the potential future purchases by Kinaxis of Shares pursuant to the NCIB and the benefits of the NCIB. By its very nature forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual performance of Kinaxis to be materially different from any anticipated performance expressed or implied by such forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated March 4, 2026 for its fiscal year ended December 31, 2025 and other risks identified in the Company’s filings with Canadian securities regulators, which filings are available on SEDAR+ at https://www.sedarplus.ca.

The risk factors referred to above are not an exhaustive list of the factors that may affect any of the Company’s forward-looking information. Forward-looking information includes statements about the future and is inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations, and opinions of management on the date the statements are made, and the Company does not assume any obligation to update such forward-looking information if circumstances or management's beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

SOURCE: Kinaxis Inc.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309385608/en/

Permalink

https://www.aetoswire.com/en/news/54440719

Contacts

Media Relations

Vanessa Cohen | Kinaxis

vcohen@kinaxis.com

647-822-8540

Investor Relations

Rick Wadsworth | Kinaxis

rwadsworth@kinaxis.com

613-907-7613